Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE versus RENOGRAFIN 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE versus RENOGRAFIN 76.
HYPAQUE vs RENOGRAFIN-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hypaque (diatrizoate sodium/diatrizoate meglumine) is an ionic, high-osmolar iodinated contrast agent. It attenuates X-rays by increasing the atomic density in tissues, providing radiographic contrast. It is not pharmacologically active but may cause physiological effects due to hyperosmolality.
Radiopaque contrast agent that attenuates X-rays by absorbing them due to its high iodine content, allowing visualization of vascular structures and organs during radiographic procedures.
Intravenous: 50-300 mL of 30-60% solution depending on procedure; maximum 5 mL/kg. Intra-arterial: 5-80 mL per injection. Intrathecal: Not recommended due to neurotoxicity.
Intravenous administration of 50-100 mL (14.1-28.2 g iodine) as a single dose for angiography; dose varies by procedure and patient size.
None Documented
None Documented
The terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In renal impairment, half-life is prolonged and may exceed 20 hours in severe cases, requiring dose adjustment.
Terminal elimination half-life: 1–2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min)
The drug is excreted unchanged primarily by the kidneys via glomerular filtration. Renal excretion accounts for >95% of elimination; biliary/fecal excretion is negligible (<5%).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<5%)
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent